On Google Finance, when you look up ECYT, you see an article about how Europe will be making a decision on Endocyte's drug. It goes on to say that the European officials will request an oral presentation suggesting a 'controversy" with the drug. To those of you that listened to the conference call, didn't Mr. Ellis state though that the EMA had NOT requested an oral presentation? I'm wondering where the discrepancy is or maybe I misunderstood?
Hey, guys. Thanks for letting me to ask the question. Just two quick questions. And first one, I am not sure if you are willing to answer, but I think I remember you guys talking with respect to the CHMP process that you maybe asked to present in front of the agency, can you describe whether or not that’s taking place if that’s still sort of a checkpoint in this process or not?
Ron Ellis - President and Chief Executive Officer
Yes. Right now, we don’t have any indication that there would be an oral presentation, but we probably won’t be for sure until we kind of finalized the schedule with them, but right now, no, we don’t know, that’s how it occurred.